Malassezia Sympodialis (Mala s 5) IgE

If you have eczema that flares on your face, scalp, or neck and standard treatments keep falling short, a skin yeast you have never noticed might be part of the problem. Malassezia sympodialis lives on nearly everyone's skin, but in some people the immune system reacts to it as an allergen, fueling stubborn, head-and-neck-predominant atopic dermatitis.

This test measures Mala s 5 (a specific protein from Malassezia sympodialis) IgE in your blood, one piece of a broader Malassezia allergy picture. It is a targeted test, not part of a routine allergy panel, and it helps identify a specific eczema subgroup where antifungal treatment may help, although the supporting evidence for antifungal therapy remains limited.

Why This Test Matters

In adults with atopic dermatitis, IgE antibodies against Malassezia show up in roughly 35 to 52 percent of patients, but in less than 1 to 12 percent of people with other skin conditions or no skin disease at all. That contrast is what makes this measurement clinically useful: when it is positive, it points toward a Malassezia-driven component rather than a generic allergy or unrelated rash.

The pattern is even stronger in head-and-neck atopic dermatitis. A meta-analysis found that about 79 percent of patients with this pattern carry Malassezia-specific IgE, although the analysis noted significant variation by study quality, with higher-quality studies reporting prevalence closer to 95 percent and lower-quality studies closer to 58 percent. Individual studies report anywhere from 49 to 80 percent positivity in head-and-neck cases. Severity tracks with these numbers too, with more severe adult eczema linked to higher Malassezia-specific IgE.

What Mala s 5 Actually Is

Mala s 5 is one of more than a dozen individual proteins from Malassezia sympodialis that the immune system can recognize. When your body produces IgE against Mala s 5, B cells (the immune cells that make antibodies) have specifically locked onto that protein after being primed by repeated exposure to the yeast on your skin.

IgE is the antibody class that drives classic allergic reactions. Once made, it binds to mast cells and basophils, immune cells that release inflammatory chemicals when they later encounter the same protein. Higher skin pH, which is common in eczema-prone skin, makes the yeast release more of these allergenic proteins, increasing the chance of building up IgE responses.

Mala s 5 is one piece of a larger sensitization profile. In studies that tested ten recombinant Malassezia proteins side by side, individual components were recognized in 2 to 30 percent of atopic dermatitis patients, and Mala s 13 (not Mala s 5) was the most commonly detected. Earlier work using skin tests pointed to Mala s 1, 5, 6, and 9 as the most frequently bound. The takeaway: Mala s 5 is part of the story, not the whole story.

Head-and-Neck Atopic Dermatitis

Head-and-neck atopic dermatitis is a stubborn pattern of eczema that affects the face, scalp, ears, and neck in adults. This region is where Malassezia naturally thrives, and it is where Malassezia-driven inflammation tends to show up most clearly. A positive Malassezia-specific IgE result is one of the few biomarkers that helps distinguish this subtype from look-alike conditions such as seborrheic dermatitis, where Malassezia-specific IgE is typically absent, although no single biomarker is fully diagnostic on its own.

In patients with head-and-neck atopic dermatitis and confirmed Malassezia hypersensitivity, antifungal therapy has produced clinical responses and improved quality of life in observational reports, although high-quality trial evidence supporting these treatments remains sparse. This is one of the rare cases where an IgE blood result may directly open a specific treatment pathway worth discussing with your clinician.

Disease Severity Signal

Among adults with atopic dermatitis, Malassezia-specific IgE correlates with disease severity scores, with higher antibody levels appearing in people with more severe, widespread, or harder-to-control eczema. The same patients often have elevated total IgE and antibodies to multiple microbial triggers, suggesting a more reactive, polysensitized immune profile.

There is also evidence of autoallergy linked to Malassezia. One of its allergens (Mala s 11) closely resembles a human protein called manganese superoxide dismutase, and IgE against it can cross-react with your own tissue. This molecular mimicry has been documented in atopic dermatitis patients and is associated with more severe disease.

Atopic Dermatitis in Children

Sensitization to Malassezia is not just an adult phenomenon. In children with atopic dermatitis, about 17 percent show Malassezia-specific IgE, including infants as young as 4 months. In a long-term study of children with both eczema and food allergy, 20 percent had IgE to Malassezia sympodialis by age 11, and 27 percent had IgE to a broader Malassezia mix.

The risk is highest in children with severe, widespread early eczema and very high total IgE. Greater eczema extent in infancy predicted Malassezia sensitization ten years later, suggesting that early, severe skin barrier disruption sets up long-term immune reactivity to this yeast.

How This Compares to Other Allergy Tests

Standard aero-allergen and food allergy panels typically do not include Malassezia. Even when a generic IgE panel looks normal, you can still carry meaningful Malassezia-specific IgE that is only detectable when the test is specifically ordered.

There is also an important nuance within Malassezia testing itself. A test using only Malassezia sympodialis (the m70 extract) can miss roughly 20 percent of people who are actually sensitized to other Malassezia species. Component-resolved testing of individual proteins like Mala s 5 detects about 44 percent of atopic dermatitis patients, similar to the broader extract test, but the patterns it reveals can refine which proteins are driving your reaction.

When Results Can Be Misleading

• Limited single-component view: a negative Mala s 5 result does not rule out sensitization to other Malassezia proteins or other species. Sensitization often clusters across several components rather than one.
• Specimen and species choice: tests based on a single Malassezia species can miss about 20 percent of sensitized patients who react primarily to other species, so a negative result on a narrow assay is not a clean all-clear.
• Cross-reactivity with human proteins: IgE to certain Malassezia proteins can cross-react with human manganese superoxide dismutase, blurring whether the response reflects yeast exposure, internal autoallergy, or both.
• No established short-term confounders for this specific marker: the available studies do not document acute illness, fasting, exercise, or specific medications that meaningfully shift Mala s 5 IgE levels in the short term.

Tracking Your Trend

Allergen-specific IgE levels can shift over time with skin barrier changes, treatment, and ongoing yeast exposure. A single number is most useful when paired with your clinical picture and a follow-up reading. If you are starting antifungal therapy, immunotherapy, or a biologic such as dupilumab, retesting can show whether your immune system is shifting away from this trigger.

As a reasonable, opinion-based approach (no specific retesting interval has been validated in trials): consider a baseline now, and a recheck in 3 to 6 months if you are actively treating eczema or specifically targeting Malassezia. After that, annual checks may be useful as part of broader allergy monitoring, particularly if symptoms flare on the head, neck, or scalp.

What to Do With an Unexpected Result

If your Mala s 5 or broader Malassezia IgE is positive and you have head-and-neck eczema or severe atopic dermatitis, the most useful next steps are pattern-matching rather than chasing a single number. Pair the result with a total IgE measurement, a broader aero-allergen and food panel, and ideally testing against a Malassezia species mix or recombinant components to capture sensitization the narrow extract may miss.

A dermatologist or allergist familiar with atopic dermatitis can help interpret whether the pattern supports a trial of topical or oral antifungal therapy, more aggressive eczema management, or evaluation for biologic treatment. If your IgE is negative but eczema continues, Malassezia is less likely to be the dominant driver, and clinical attention can refocus on other triggers such as skin barrier dysfunction, food allergens, or other microbes.